Skip to content

Effectiveness of HPV Vaccine Among Adolescents and Reproductive Women

Effectiveness of Single Dose or Two Doses of HPV Vaccine Among Adolescents and Reproductive Women: A Test-negative Control Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06220747
Enrollment
760
Registered
2024-01-24
Start date
2024-03-29
Completion date
2025-06-30
Last updated
2024-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hpv

Brief summary

To assess the effectiveness of HPV vaccine 2 doses or less to prevent HPV high risk infection among adolescents and adults. We conduct the test-negative control study including 12-45 women who interest to do a check-up pap smear. Cases were women who met the inclusion criteria and tested positive for HPV DNA, and controls were defined as women who met inclusion criteria but tested negative. For the proposed HPV VE study, we will enroll nine controls for each enrolled case. The participants will be interviewed about their demographics and vaccine histories. Potential confounders data will be collected by interview or self- report questionnaire. HPV DNA test will be done by urine or self-cervical sampling (optional). In case the participant has previous HPV test result within 1 year, the result will be recorded and analysed without repeating the test.

Interventions

None listed

Sponsors

National Research Council of Thailand
CollaboratorOTHER_GOV
Mahidol University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
OTHER

Eligibility

Sex/Gender
FEMALE
Age
12 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Women aged 12-45 who willing to do HPV test check-up. * Subject has provided written informed consent prior to performance of any study-specific procedures and is willing and has means to be contacted and to contact the investigator during the study. * Based on clinical judgment, the participant with underlying chronic disease who has stable and well-controlled medical conditions.

Exclusion criteria

* Participant with history of total hysterectomy and loop electrosurgical excision procedure. * Participant who received 3 doses HPV vaccine. * Any condition that might confound the interpretation of vaccine effectiveness by investigator

Design outcomes

Primary

MeasureTime frameDescription
The real world effectiveness of HPV vaccine 2 doses or less to prevent HPV high risk infection among women aged 12-451 visit (1 day)Estimation of overall vaccine effectiveness For the planned analyses, the log odds of disease for individuals in matched sets will be modelled using the following conditional logistic model:Model 1 : Log (oddcase) = α¬i + β e(HPV\_vaccination) + β1(cov\_1) +β2(cov\_2) + ... + βk(cov\_k)where αi is the stratum-specific constant term for each matched set, βe is the parameter coefficient for the exposure of interest (receipt of HPV vaccine), and β1 through βk are the parameter coefficients for each covariate included in the model to control for confounding. Our modelling strategy will be to create models that always contain the exposure variable of interest (receipt of HPV vaccine) and additional covariates as needed.

Countries

Thailand

Contacts

Primary ContactSupitcha Kamolratanakul, Asst.Prof.
supitcha.kam@mahidol.edu66 81 699 6660

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026